Navigation Links
ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
Date:6/13/2008

gned to evaluate the safety and efficacy of ACTEMRA plus methotrexate compared with placebo plus methotrexate in patients who failed to adequately respond to anti-TNF medications alone. Between 12-18 percent of the study population experienced three or more prior anti-TNF failures. Patients were randomized to receive either ACTEMRA intravenously (4 mg/kg or 8 mg/kg) plus methotrexate every four weeks or placebo infusions plus methotrexate weekly for 24 weeks. The study included 499 patients from 128 trial sites in 13 countries, including the United States.

In the study, 50 percent, 29 percent and 12 percent of RA patients treated with ACTEMRA (8 mg/kg) plus methotrexate achieved ACR20, ACR50 and ACR70, respectively, compared with 10 percent, 4 percent and 1 percent, respectively, of patients treated with placebo infusions plus methotrexate weekly.

Treatment with ACTEMRA and methotrexate showed significant clinical benefits even in the subgroup analysis of difficult-to-treat patients who received up to three anti-TNFs therapies that failed. Furthermore, disease remission (DAS28 <2.6) was demonstrated in 30 percent of ACTEMRA patients compared with 1.6 percent of patients in the control group.

The most common adverse reactions reported more frequently in the ACTEMRA arms of the RADIATE trial were nausea, headache, nasopharyngitis, diarrhea, and upper respiratory tract infections.

"These study results are very promising for RA patients who need a variety of treatment options, particularly when they have failed to achieve adequate pain and symptom relief with anti-TNF therapies," said Professor Paul Emery, lead study investigator of the RADIATE trial and Professor of Rheumatology, University of Leeds in the United Kingdom.

In both studies, patients treated with ACTEMRA alone or with methotrexate achieved greater improvements in quality-of-life measures, including fatigue, pain, and physical and mental functions, compared with methotrex
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
2. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
3. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
4. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
5. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
6. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
7. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
10. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
11. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , August 27, 2014 ... Equipment Market By Products (Dental Radiology, CAD/CAM, Dental Chairs, Dental ... published by MarketsandMarkets, the global Dental Equipment Market is ... $5,416.3 million in 2014, growing at a CAGR ... Browse 95 market data tables and 61 figures ...
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com announces that ... its catalogue: Global Heart Valve Repair ... http://www.reportlinker.com/p02316644/Global-Heart-Valve-Repair-and-Replacement-Market-2014-2018.html About Heart Valve Repair ... human heart which control the flow of blood ... heart valve diseases such as valvular stenosis, valvular ...
(Date:8/27/2014)... 27, 2014  Hill-Rom Holdings, Inc. (NYSE: ... presentation at the Morgan Stanley Global Healthcare Conference on ... You are invited to listen to the live discussion ... access it directly at http://cc.talkpoint.com/morg007/090814a_ac/?entity=26_7CLOGQP .  A recorded ... after conclusion of the live event and accessible at ...
Breaking Medicine Technology:Dental Equipment Market Worth $7,138.9 Million by 2019 2Dental Equipment Market Worth $7,138.9 Million by 2019 3Global Heart Valve Repair and Replacement Market 2014-2018 2Global Heart Valve Repair and Replacement Market 2014-2018 3Global Heart Valve Repair and Replacement Market 2014-2018 4
... ... ... - SORT OUT III Data Presented at American College of Cardiology Meeting,in Atlanta and Published in the Lancet , ... , , ...
... Md. , March 17 Micromet, Inc. (Nasdaq: MITI ) announced today the closing of its previously ... shares of common stock. As a result, Micromet sold a total of 11.5 million shares of its common stock at ... ... , , ...
Cached Medicine Technology:Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 2Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 3Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 4Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 5Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 6Micromet Closes $80.5 Million Public Offering of Common Stock 2Micromet Closes $80.5 Million Public Offering of Common Stock 3Micromet Closes $80.5 Million Public Offering of Common Stock 4
(Date:8/27/2014)... 27, 2014 With most forms ... sense to use hearing protection when exposed to ... are many different forms of hearing protection ... provide hearing protection training and devices for workers ... industries. The National Institute of Occupational Safety and ...
(Date:8/27/2014)... time you experienced worrisome medical symptoms, did you ... professional? If so, you,re not alone. Consumers are ... support groups to gather anecdotal information and advice, ... trustworthy sources. New research to be presented at ... the characteristics of consumers who use the Internet ...
(Date:8/27/2014)... 27, 2014 (HealthDay News) -- A new genetic discovery ... fight the bowel disorder, researchers report. The ... affect how their genes work, and said these changes ... raising the possibility of a simple diagnostic test for ... disease develops and suggest possible gene targets for new ...
(Date:8/27/2014)... An experimental drug designed to help regulate the blood,s iron ... of inflammation, according to results from the first human ... Blood , the Journal of the American ... occurs when red blood cells are in short supply or ... body does not get enough oxygen, since there are fewer ...
(Date:8/27/2014)... 8/27/14)Dartmouth cancer researchers developed and tested an advanced ... interactions that contribute to disease as published yesterday ... The approach fills a gap in current analyses. ... interactions among genetic and environmental factors. When many ... versus those that reflect chance combinations among affected ...
Breaking Medicine News(10 mins):Health News:Hearing Health Solutions Now Offering a Full Line of Occupation Hearing Protection Services and Expanded Line of Ear Protection Products 2Health News:Hearing Health Solutions Now Offering a Full Line of Occupation Hearing Protection Services and Expanded Line of Ear Protection Products 3Health News:Educated consumers more likely to use potentially unreliable online healthcare information 2Health News:Scientists Spot Genetic Clues to Crohn's Disease 2Health News:Drug represents first potential treatment for common anemia 2Health News:Dartmouth isolates environmental influences in genome-wide association studies 2
... may lower the risk of a type of kidney malignancy ... ,The researchers at Brigham and Women's Hospital in Boston found ... alcoholic beverage a day were about 30 percent less likely ... they found in people who drank beer, wine or liquor. ...
... US President set a target of ten years for developing ... ,"We have learned in that period of time ... senior vice president for research and development at the International ... vaccine research increased from $186 million in 1997 to $759 ...
... rates among Japanese have generally tended to be high. Now ... hit a record 65 in 2006, compared to 42 ... ,The number of workers who received compensation for work-induced ... percent from a year earlier, he said. The number of ...
... of Health and Child Welfare, Dr. David Parirenyatwa, says ... West have severely compromised the country's health delivery ... ongoing World Health Assembly in Geneva, Switzerland, to join ... these sanctions. He calls the sanctions an unacceptable ...
... have agreed on a $5-billion initiative with major banks to ... the first such enterprise to combat climate change. ... this week with a summit in New York attended by ... to discuss climate change. ,Clinton's initiative launched on ...
... developed a model that could improve the treatment ... combine current clot-busting medication with below-normal body temperatures ... lowering a patients temperature reduces the metabolic activity ... cell damage and death. ,The FDA-approved ...
Cached Medicine News:Health News:AIDS Vaccine Still a Long Way Off 2Health News:Workplace Stress Leads to Rising Suicide Rate in Japan 2Health News:Sanctions Imposed On Zimbabwe Can Threaten International Health Security 2Health News:World Cities Join Hands to Combat Climate Change 2Health News:Researchers Develop Model That Aids in Treating Stroke Patients 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: